Cellectar Biosciences Inc Total Liabilities
Cellectar Biosciences Inc total liabilities. Based on the latest financial reports, Cellectar Biosciences Inc (CLRB) has total liabilities worth $5.06 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CLRB financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cellectar Biosciences Inc (2004–2025)
Total liabilities of Cellectar Biosciences Inc from 2004 to 2025. This chart illustrates how Cellectar Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore CLRB long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Cellectar Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Cellectar Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Automobile &Pc
KO:015260
|
Korea | ₩71.04 Billion |
|
Trinity Biotech plc
NASDAQ:TRIB
|
USA | $177.15 Million |
|
ROKMASTER Resources Corp
V:RKR
|
Canada | CA$3.45 Million |
|
Agri-Tech (India) Limited
NSE:AGRITECH
|
India | Rs10.10 Million |
|
PT Winner Nusantara Jaya Tbk
JK:WINR
|
Indonesia | Rp107.74 Billion |
|
Youxin Technology Ltd Class A Ordinary shares
NASDAQ:YAAS
|
USA | $3.87 Million |
|
FBS Global Limited Ordinary Shares
NASDAQ:FBGL
|
USA | $14.90 Million |
|
Inca Minerals Ltd
AU:ICG
|
Australia | AU$283.19K |
Liability Composition Analysis (2004–2025)
This chart breaks down Cellectar Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cellectar Biosciences Inc (CLRB) total assets.
Liquidity & Leverage Metrics
Cellectar Biosciences Inc Total Liabilities Ratios Explained
Cellectar Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellectar Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellectar Biosciences Inc (2004–2025)
The table below shows the annual total liabilities of Cellectar Biosciences Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.06 Million | -54.75% |
| 2024-12-31 | $11.18 Million | -56.76% |
| 2023-12-31 | $25.85 Million | +114.46% |
| 2022-12-31 | $12.05 Million | +190.01% |
| 2021-12-31 | $4.16 Million | +7.55% |
| 2020-12-31 | $3.86 Million | +21.10% |
| 2019-12-31 | $3.19 Million | +77.98% |
| 2018-12-31 | $1.79 Million | -15.30% |
| 2017-12-31 | $2.12 Million | +18.62% |
| 2016-12-31 | $1.78 Million | -69.99% |
| 2015-12-31 | $5.95 Million | +122.42% |
| 2014-12-31 | $2.67 Million | -47.75% |
| 2013-12-31 | $5.12 Million | +287.67% |
| 2012-12-31 | $1.32 Million | +21.97% |
| 2011-12-31 | $1.08 Million | -13.71% |
| 2010-12-31 | $1.25 Million | -96.50% |
| 2009-12-31 | $35.83 Million | +408.15% |
| 2008-12-31 | $7.05 Million | -58.47% |
| 2007-12-31 | $16.98 Million | +1192.66% |
| 2006-12-31 | $1.31 Million | +504.83% |
| 2005-12-31 | $217.16K | -95.13% |
| 2004-12-31 | $4.46 Million | -- |
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with re… Read more